药物发现市场规模、份额、成长分析，依药物类型、技术、製程、最终用户、地区产业预测，2024-2031

2022年全球药物发现市场规模为957亿美元，从2023年的1020.2亿美元成长到2031年的1701.1亿美元，复合年增长率预计为6.6%。

在疾病流行、技术进步和个人化医疗需求不断增长的推动下，全球药物发现市场预计将显着增长。我猜创新的研究和开发倡议侧重于新的药物标靶和有效的治疗方法，采用结合基因组学、蛋白质组学和计算生物学的跨学科方法来阐明疾病机制并简化药物发现。此外，利用高性能筛检、人工智慧、巨量资料分析等最尖端科技将显着提高药物开发的效率和成功率。随着对精准医疗和标靶治疗的重视，市场预计在未来几年将显着扩大，使该公司成为医疗行业的重要参与企业。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 世界市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及前景

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特分析与影响
  • 竞争公司之间的敌对关係
  • 替代品的威胁
  • 买方议价能力
  • 新进入者的威胁
  • 供应商的议价能力

主要市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 监管环境
• 专利分析

药物发现市场规模：依药物类型及复合年增长率（2024-2031）

• 市场概况
• 小分子药物
• 生技药品

药物发现市场规模：依技术及复合年增长率（2024-2031）

• 市场概况
• 高效率筛检（HTS）
• 药物基因组学
• 组合化学
• 奈米科技
• 其他的

药物发现市场规模：依流程及复合年增长率（2024-2031）

• 市场概况
• 目标选择
• 先导药物最适化
• 从命中到线索的识别

药物发现市场规模：依最终用户和复合年增长率（2024-2031）

• 市场概况
• 製药公司
• 合约研究组织（CRO）
• 学术研究所
• 其他的

药物发现市场规模和复合年增长率（2024-2031）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 西班牙
  • 法国
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
• 产品系列分析
• 按细分市场分類的份额分析
• 收益与前一年同期比较（2021-2023）

主要企业简介

• Pfizer Inc.
• Novartis AG
• Merck & Co., Inc.
• Johnson & Johnson
• Roche Holding AG
• Sanofi SA
• GlaxoSmithKline plc
• AstraZeneca plc
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• AbbVie Inc.
• Amgen Inc.
• Bayer AG
• Takeda Pharmaceutical Company Limited
• Gilead Sciences, Inc.
• Biogen Inc.
• Boehringer Ingelheim GmbH
• Vertex Pharmaceuticals Incorporated
• Regeneron Pharmaceuticals, Inc.
• Novo Nordisk A/S

结论和建议

Global Drug Discovery Market size was valued at USD 95.70 billion in 2022 and is poised to grow from USD 102.02 billion in 2023 to USD 170.11 billion by 2031, growing at a CAGR of 6.6% during the forecast period (2024-2031).

The Global Drug Discovery market is poised for substantial growth, fueled by rising disease prevalence, technological advancements, and a heightened demand for personalized medicine. Innovative R&D initiatives are focusing on novel drug targets and effective therapeutics, with an interdisciplinary approach that incorporates genomics, proteomics, and computational biology to unravel disease mechanisms and streamline drug discovery. Furthermore, the utilization of cutting-edge technologies such as high-throughput screening, artificial intelligence, and big data analytics significantly improves the efficiency and success rates of drug development. As the emphasis on precision medicine and targeted therapies intensifies, the market is set for remarkable expansion in the upcoming years, positioning it as a key player in the healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Drug Discovery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Drug Discovery Market Segmental Analysis

Global Drug Discovery Market is segmented by drug type, technology, process, end user and region. Based on drug type, the market is segmented into small molecule drugs and biologic drugs. Based on technology, the market is segmented into high throughput screening (HTS), pharmacogenomics, combinatorial chemistry, nanotechnology and other. Based on process, the market is segmented into target selection, lead optimization and hit-to-lead identification. Based on end user, the market is segmented into pharmaceutical companies, contract research organizations (CROs), academic and research institutes and other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Drug Discovery Market

A key driver of the Global Drug Discovery market is the escalating prevalence of chronic and infectious diseases. The growing rates of conditions such as cancer, cardiovascular diseases, and various infectious illnesses have intensified the demand for innovative and effective pharmaceutical solutions. This surge in disease incidence compels pharmaceutical companies and research institutions to prioritize investment in drug discovery and development efforts, accelerating the creation of new treatments and therapies to address these pressing health challenges. As a result, the landscape of drug discovery is becoming increasingly vital in the quest for improved healthcare outcomes and enhanced patient well-being worldwide.

Restraints in the Global Drug Discovery Market

The Global Drug Discovery market faces significant restraints primarily due to the high costs and the lengthy nature of the drug development process. The journey from drug discovery to market approval is intricate and resource-intensive, necessitating considerable investments in research, clinical trials, and navigating regulatory requirements. This complexity, coupled with stringent safety and efficacy standards, extends development timelines and inflates overall expenses. As a result, these factors can hinder the accessibility and affordability of innovative medications, creating challenges for stakeholders involved in the drug discovery process and potentially impacting the market's growth trajectory.

Market Trends of the Global Drug Discovery Market

In the Global Drug Discovery market, a significant trend is the escalating integration of artificial intelligence (AI) and machine learning (ML) technologies, catalyzing a transformative shift in the drug development landscape. These innovative technologies facilitate the rapid analysis of extensive biological datasets, allowing for precise identification of drug-target interactions and streamlined workflows. AI-driven virtual screening and molecular modeling not only enhance the efficiency of drug candidate identification but also reduce overall costs and timelines associated with the drug discovery process. As a result, this trend is poised to improve success rates in clinical trials and foster the emergence of novel therapeutics, ultimately reshaping the pharmaceutical industry's approach to drug development.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis

Global Drug Discovery Market Size by Drug Type & CAGR (2024-2031)

• Market Overview
• Small Molecule Drugs
• Biologic Drugs

Global Drug Discovery Market Size by Technology & CAGR (2024-2031)

• Market Overview
• High Throughput Screening (HTS)
• Pharmacogenomics
• Combinatorial Chemistry
• Nanotechnology
• Other

Global Drug Discovery Market Size by Process & CAGR (2024-2031)

• Market Overview
• Target Selection
• Lead Optimization
• Hit-to-Lead Identification

Global Drug Discovery Market Size by End User & CAGR (2024-2031)

• Market Overview
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic and Research Institutes
• Other

Global Drug Discovery Market Size & CAGR (2024-2031)

• North America (Drug Type, Technology, Process, End User)
  • US
  • Canada
• Europe (Drug Type, Technology, Process, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Drug Type, Technology, Process, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America, (Drug Type, Technology, Process, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Technology, Process, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation